Access to anti-retroviral drugs, female in Serbia

Serbia: Access to anti-retroviral drugs, female was 69.0% in 2024. ▲ Rising

Latest (2024)
69.0%
Change on year
down 2.8%
World rank
84th
of 141 countries
All-time high
76.0%
in 2017
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, female in Serbia, 2000–2024

0204060802000201220242000: 0 %2001: 0 %2002: 0 %2003: 22 %2004: 28 %2005: 34 %2006: 36 %2007: 37 %2008: 40 %2009: 42 %2010: 45 %2011: 48 %2012: 51 %2013: 54 %2014: 57 %2015: 62 %2016: 68 %2017: 76 %2018: 70 %2019: 73 %2020: 70 %2021: 70 %2022: 70 %2023: 71 %2024: 69 %

Source: UNAIDS estimates. Measured in %.

Analysis

In 2024, access to anti-retroviral drugs, female in Serbia stood at 69.0%.

That represents a change of down 2.8% on the previous year and up 21.1% over ten years.

Over the whole period, access to anti-retroviral drugs, female in Serbia peaked at 76.0% in 2017 and was at its lowest, 0.0%, in 2000.

That places Serbia 84th out of 141 countries with data for 2024, putting it in the middle of the range.

The long-run direction has been consistently rising across the 25 years of available data.

Access to anti-retroviral drugs, female in Serbia, year by year

Annual values for Access to anti-retroviral drugs, female (%) in Serbia, 2000 to 2024.
Year % Change
2000 0.0%
2001 0.0%
2002 0.0%
2003 22.0%
2004 28.0% +27.3%
2005 34.0% +21.4%
2006 36.0% +5.9%
2007 37.0% +2.8%
2008 40.0% +8.1%
2009 42.0% +5.0%
2010 45.0% +7.1%
2011 48.0% +6.7%
2012 51.0% +6.2%
2013 54.0% +5.9%
2014 57.0% +5.6%
2015 62.0% +8.8%
2016 68.0% +9.7%
2017 76.0% +11.8%
2018 70.0% -7.9%
2019 73.0% +4.3%
2020 70.0% -4.1%
2021 70.0% +0.0%
2022 70.0% +0.0%
2023 71.0% +1.4%
2024 69.0% -2.8%

Averages by decade

DecadeAverage LowestHighest Years
2000s 23.9% 0.0% 42.0% 10
2010s 60.4% 45.0% 76.0% 10
2020s 70.0% 69.0% 71.0% 5

Countries ranked near Serbia

  1. 81 Lao People's Democratic Republic 71.0% compare
  2. 82 Estonia 70.0% compare
  3. 82 Somalia 70.0% compare
  4. 84 Lebanon 69.0% compare
  5. 86 Dominican Republic 68.0% compare
  6. 86 Mauritania 68.0% compare

See the full ranking of 160 places →

More gender data for Serbia

All data for Serbia →

Frequently asked questions

What is access to anti-retroviral drugs, female in Serbia?
Access to anti-retroviral drugs, female in Serbia was 69.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, female recorded in Serbia?
The highest recorded value was 76.0% in 2017.
What is the lowest access to anti-retroviral drugs, female recorded in Serbia?
The lowest recorded value was 0.0% in 2000.
How does Serbia rank for access to anti-retroviral drugs, female?
Serbia ranks 84th out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, female rising or falling in Serbia?
Over the last ten years it is up 21.1%. The long-run trend across the full record is rising.
Where does this Serbia data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, female (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, female in Serbia. Statizoid, drawing on UNAIDS estimates. Retrieved 11 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/serbia/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/serbia/">Access to anti-retroviral drugs, female in Serbia</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, female (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,925 data points, 2000–2024
Last refreshed

The percentage of adult females living with HIV who are receiving antiretroviral therapy.